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TMB LightMix kit Trichomonas vaginalisTrichomonas vaginalis causes the most common non-viral sexual
transmitted infection (STI) with annually 248million new cases world-
wide (World Health Organization DoRHaR, 2011). T. vaginalis occurs
often as an asymptomatic infection and is in most cases untreated.
When symptomatic, women may experience itch, changes in vaginal
discharge, lower and upper reproductive tract disease syndromes, in-
cluding vaginitis, cervicitis, increased risk for tubal pathology, and pelvic
inﬂammatory disease (PID) (McGowin et al., 2014; Soper, 2004). Un-
treated T. vaginalis infection affects sexual, reproductive and obstetric
health andmay facilitate transmission of other STIs, including anHIV in-
fection. T. vaginalis infections are more likely for HIV acquisition, an in-
creased risk of preterm labor, an increased risk of PID, and an association
is found between a T. vaginalis infection with a concurrent Chlamydia
infection (Mavedzenge et al., 2010; Naidoo and Wand, 2013). A
T. vaginalis infection is a curable STI, which is why diagnostic testing re-
mains important to prevent complications.
Microscopic examination of wetmount smear and/or culture are the
methods for detection of T. vaginalis and are currently most commonly
used. However, wet mount is described to be insensitive compared to
culture (53%) (Kissinger, 2015). Another disadvantage of wet mount
microscopy is that should be read within ten minutes of collectionical Center, Laboratory of
on Control, De Boelelaan 1108,
. This is an open access article under(Kissinger, 2015). A disadvantage of culture is that T. vaginalis is unde-
tectable for months after treatment with metronidazole in HIV positive
women (Gatski et al., 2010; Peterman et al., 2009).
More sensitive techniques are DNA or RNA ampliﬁcation tests to de-
tect T. vaginalis: PCR-based methods report 40% more positive samples
than culture (Caliendo et al., 2005). To facilitate implementation of
these molecular tests in the routine microbiology laboratory, combina-
tion tests have been developed that combine multiple pathogens (e.g.
Chlamydia trachomatis, Neisseria gonorrhoeae, and T. vaginalis) in a sin-
gle assay. The Presto Assay (Microbiome Ltd., Houten, The
Netherlands) is a dual detection assay for C. trachomatis and
N. gonorrhoeae. The Prestoplus CT/NG/TV assay (Microbiome Ltd.,
Houten, The Netherlands) is a triple detection assay, with an additional
T. vaginalis detection, which can be used on a variety of open PCR sys-
tems. The Presto Assay has already been compared to the Roche
cobas® 4800 CT/NG assay, and showed comparable results (de Waaij
et al., 2015). In the current study, we evaluated the Prestoplus CT/NG/
TV assay for detection of T. vaginalis. Due to the unavailability of a
Roche T. vaginalis Assay, we compared it to the TIB MOLBIOL (TMB)
LightMix Kit Trichomonas vaginalis Assay run in the open channel of
the Roche Z480 using dry collected vaginal and rectal swabs.
Samples for this evaluation were obtained from a cross-sectional
study that was conducted at primary healthcare facilities across the
Mopani District, South Africa (Peters et al., 2014). All women (n =
615) aged 18 to 49 years who reported to have been sexually active
during the last 6 months were eligible; patient information wasthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Flow diagram of the results of the vaginal samples for T. vaginalis. The 615 samples,
tested by Prestoplus and LightMix Kit T. vaginalis resulted in concordant and discrepant
results. The Qiagen assay was used for discrepant samples and the alloyed gold standard
was deﬁned as two concurring results. Sensitivity, speciﬁcity, PPV, and NPV were
calculated.
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worker-collected vaginal and rectal dry swabs (Copan Diagnostics,
Brescia, Italy) were obtained and frozen at −20 °C for storage until
further processing. The study was approved by the Human Ethics
Research Committee of the University of the Witwatersrand, South
Africa (Ref. M110726).
Material was transported on dry ice to Amsterdam, The Netherlands
for processing. Samples were resuspended in 1 ml of sterile phosphate-
buffered saline (PBS), vortexed and diagnostically tested for C.
trachomatis, N. gonorrohoeae, and T. vaginalis infection. 200 μl of each
sample were used for DNA extraction and the rest was stored at
−20 °C.
For the Prestoplus Assay, DNA was isolated using the High Pure
PCR Template Preparation (HPPTP) Kit (Roche Diagnostics, Basel,
Switzerland) as per manufacturer's instructions prior to T. vaginalis
DNA detection was performed by the Prestoplus Assay according to the
manufacturer's instructions. Detection was done on the LightCycler II
(Roche Diagnostics, Basel, Switzerland).
For the TMB LightMix Kit Trichomonas vaginalis (Berlin, Germany)
assay, DNA was isolated on the Roche X480 and detection on the
Roche Z480.
Samples with discordant results between the Prestoplus and
LightMix Kit Trichomonas vaginalis assay were again isolated by the
chemagic MSM I system (PerkinElmer, Inc., Waltham, MA, USA). Sam-
pleswere analyzed by the QiagenMicrobial DNAqPCR kit for T. vaginalis
(Hilden, Germany) on the LightCycler II. The alloyed gold standard
(Spiegelman et al., 1997) was deﬁned as concordant results for the
Prestoplus and LightMix Kit T. vaginalis assays, or, for the samples with
discordant results between these tests, as the concurring result of either
test and the Qiagen test.
Performances (sensitivity, speciﬁcity, positive predictive value
(PPV), and negative predictive value (NPV)) were assessed for both
assays and discrepancy analyses were performed with a third assay,
the Qiagen Microbial DNA qPCR kit for T. vaginalis.
Of the 615 samples tested, 98 (16%) had a positive result with the
Prestoplus Assay and 109 (18%) with the LightMix Kit T. vaginalis assay.
Of these samples 96 were concordant positive. A total of 504 samples
had concordant negative T. vaginalis results. Fifteen samples had
discordant results between Prestoplus and LightMix Kit T. vaginalis
assay. These were analyzed by the Qiagen Microbial DNA qPCR assay.
Qiagen Microbial DNA qPCR assay conﬁrmed the two Prestoplus posi-
tive/LightMix Kit T. vaginalis negative to be false negative (compared
to the alloyed gold standard), eight samples to be false positive
(compared to the alloyed gold standard) for LightMix Kit T. vaginalis,
and ﬁve samples to be false negative for Prestoplus. See Fig. 1.
Sensitivity, speciﬁcity, and positive and negative predictive values of
the Prestoplus and LightMix Kit T. vaginalis assays were calculated
against the alloyed gold standard and are comparable (Table 1).
Sensitivity and speciﬁcity for Prestoplus and LightMix Kit T. vaginalis
were 95.2% and 98.1%, respectively. Further details can be seen in
Table 1. Prestoplus and LightMix Kit T. vaginalis showed comparable
results compared to the alloyed gold standard (McNemar p = 0.06
and p = 0.1, respectively). In addition, discrepant results were com-
pared based on the protozoan load (Cp (crossing point)-value).
LightMix Kit T. vaginalis false positive results show a signiﬁcantly
lower load in comparison to LightMix Kit T. vaginalis true positives
(40.2 vs. 32.5; p= 0.0002).
An often usedmethod for detecting a T. vaginalis infection inwomen
is culture of vaginal specimens. Culture, however, has a low sensitivity
compared to the most currently introduced PCR methods and requires
microscopic evaluation which is very time consuming and standardiza-
tion of the interpretation of positivity is ambiguous (Sena et al., 2007).
In the last decade, several PCR tests have been developed and demon-
strated to have a higher sensitivity and speciﬁcity than culture. Limited
studies have been performed comparing culture and PCR for the detec-
tion of T. vaginalis. PCR has been compared to culture and sensitivity of84% and 78% were obtained, respectively (Wendel et al., 2002). For that
study, the Papanicolaou smear was used as the golden standard, which
may lower the sensitivity.
Several studies compared PCR assays for the detection of T. vaginalis.
For instance, the performance of Gen-Probe's transcription-mediated
ampliﬁcation (TMA) assay for T. vaginalis has been compared to the
BTUB FRET PCR and showed comparable results: TMA showed sensitiv-
ity and speciﬁcity of 98.6% and 99.1% (Hardick et al., 2006). One other
study investigated the usefulness of several multiplex PCR assays for
the detection of T. vaginalis. This study included the following tests:
Anyplex™ II, Seeplex®, and AmpliSens®. The sensitivity for all three as-
says was 100.0%. The speciﬁcity was 99.9%, 100%, 99.4%, respectively.
The PPV was evidently lower for two of their three assays than in our
current study, whichmay be due to the low number of positive samples
(n= 8). The samples that were used in those studies included female
swabs, female urine, and male urine (Choe et al., 2013). Detection of T.
vaginalis by PCR in urine specimens is described to be not appropriate
in women, whereas detection by PCR in vaginal swabs is a more sensi-
tive method (Lawing et al., 2000).
This is the ﬁrst comparison study for detection of T. vaginaliswith a
high number of true positive samples (n = 103) after calculation
against the alloyed standard. In the current study we observed 17%
positive samples, after discordancy analysis.
Although this is the largest comparison study for detection of
T. vaginalis to date, our number of samples could have been higher,
but that has been balanced by the high amount of positive samples
found. Thismakes both tests suitable for detecting a T. vaginalis infection
at one infection site. Both assays performed comparably on this study
population with a high amount of positive samples and are therefore
suitable for detection of T. vaginalis.
The evaluation of dry andwet swabs has been described in detection
of C. trachomatis and N. gonorrhoeae. That study concludes that the dry
swab was as accurate as the wet swab (Gaydos et al., 2002). A study
by Eperon et al. concluded that swabs can be successfully transported
in a dry state at ambient temperaturewithout greatly altering specimen
integrity (Eperon et al., 2013). The performances of dry swabs was
previously been studied in comparison with wet swabs. Dry swabs
Table 1
Sensitivity, speciﬁcity, positive predictive value, and negative predictive value for vaginal TV for the Prestoplus assay and the LightMix Kit Trichomonas vaginalis assay.
Sens % 95% CI Spec % 95% CI PPV% 95% CI NPV% 95% CI
Prestoplus 95.28 0.93–0.97 100.0 0.99–1.00 100.0 0.99–1.00 99.0 0.98–0.99
LightMix Kit Trichomonas vaginalis 98.1 0.97–0.99 98.4 0.97–0.99 92.7 0.90–0.94 99.6 0.99–1.00
SENS, sensitivity; CI, conﬁdence interval; SPEC, speciﬁcity; PPV, positive predictive value; NPV, negative predictive value.
The alloyed gold standardwas a concurring result between the Prestoplus and LightMix Kit T. vaginalis assay, orwhen thesewere discrepant, a concurring result between either Prestoplus or
LightMix Kit T. vaginalis assay and the Qiagen Microbial DNA qPCR kit for TV. Sensitivity, speciﬁcity, PPV, and NPV for both assays and both anatomical sites were calculated against the
alloyed gold standard.
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and high concentrations (Gaydos et al., 2012). Due to the performance
of the dry swabs in several other studies, we chose to use dry swabs.
We previously compared the dual detecting Presto assay with the
currently widely used cobas® 4800 CT/NG test for the detection of
C. trachomatis and N. gonorrhoeae using dry collected vaginal and rectal
swabs with the same study population (de Waaij et al., 2015). For
C. trachomatis we detected 13% positive vaginal samples and 6.7%
positive rectal samples. In the current study, we did not include rectal
samples, due to only one positive T. vaginalis sample. The C. trachomatis
and N. gonorrhoeae results from the triple detecting Prestoplus assay
were comparable with the results from the Presto assay (data
not shown), so dry swabs appear to perform well and are useful for
C. trachomatis and N. gonorrhoeae.
In conclusion, good diagnostics are essential for prevention of fur-
ther spreading of STI in the healthy population. Therefore diagnostic
tests should display high sensitivity whereas false-positives have to be
excluded at any time. The Prestoplus assay combines multiple pathogens
in a single assay, which provides new diagnostic insights and cost
effectiveness.
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